Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIBIVAC: Heterologous vs Homologous COVID-19 Booster Combinations
NCT05142319Phase 4Completed
- Sponsor
- Tan Tock Seng Hospital
- Start
- Oct 2021
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of COVAXIN, NVX-CoV2373, tozinameran and elasomeran in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Tan Tock Seng Hospital. Primary endpoint: SARS-CoV-2 anti-spike immunoglobulins at Day 28. Started Oct 2021; status: completed.
02
Drugs
COVAXINNVX-CoV2373tozinameranelasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05142319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05142319.